View More View Less
  • 1 Szabolcs-Szatmár-Bereg megyei Jósa András Oktatókórház, 4400 Nyíregyháza, Lukács Ödön utca 4.
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $96.00

Absztrakt:

Bevezetés: A szerzők a Szabolcs-Szatmár-Bereg megyei leukémia/lymphoma regiszterben 35 év alatt (1983. január 1. és 2017. december 31. között) 4942 újonnan felismert, malignus hematológiai betegségben szenvedő, megyéjükben élő felnőtt beteg adatait rögzítették. A regisztrált esetek 34,6%-a (1711 beteg) myeloid, 65,4%-a (3231) lymphoid malignitás volt. Célkitűzés: A leukémia/lymphoma regiszterben fellelhető malignus hematológiai kórkép társulások ismertetése. Módszer: A társult hematológiai malignitásokra vonatkozó adatok részletes elemzése. Eredmények: A regisztráltak között 37 olyan beteget találtak, akikben egyidejűleg vagy egymást követően két különböző hematológiai malignitás fordult elő. Hat esetben a kétfajta megbetegedést egyidejűleg ismerték fel, szekunder myeloid malignitást nyolc, szekunder lymphoid malignitást tizenhét beteg esetében tapasztaltak, hat beteg esetében különböző non-Hodgkin-lymphomák társulását észlelték. Következtetések: A malignus hematológiai kórképek társulásával részletesen foglalkozó közlemények nem gyakoriak, betegeik adatainak az ismertetése ezért figyelmet érdemel. Az elemzett epidemiológiai adatok alapján néhány esetben ok-okozati összefüggés lehetősége is felmerül a társulások létrejöttében.

  • 1

    Jakó J, Szerafin L, Nagy P. Second cancers in hematologic malignancies (epidemiologic observations from a 20-year period). [Szekunder carcinomák malignus hematológiai betegségekben (a Szabolcs-Szatmár-Bereg megyei leukaemia/lymphoma regiszter 1983–2002 közötti adatainak elemzése).] Orv Hetil. 2005; 146: 461–469. [Hungarian]

  • 2

    Jakó J, Szerafin L, Nagy P. Second malignant haematologic diseases in patients with carcinoma (analysis of data of leukaemia/lymphoma registry in Szabolcs-Szatmár-Bereg county between 1983–2002). [Carcinomás betegekben kialakuló szekunder malignus hematológiai megbetegedések (a Szabolcs-Szatmár-Bereg megyei leukaemia/lymphoma regiszter 1983–2002. évi adatainak elemzése).] Hemat Transzf. 2005; 38: 95–104. [Hungarian]

  • 3

    Jakó J, Szerafin L, Nagy P. Hidden values of the leukaemia/lymphoma registry of Szabolcs-Szatmár-Bereg county (deduction from the epidemiologic data of a 25-year period). [A Szabolcs-Szatmár-Bereg megyei leukaemia/lymphoma regiszter rejtett értékei (negyedszázad epidemiológiai adataiból levonható következtetések).] Hemat Transzf. 2009; 42: 7–11. [Hungarian]

  • 4

    Szerafin L, Jakó J, Varju L. Occurrence of associated tumours in chronic lymphocytic leukemia. [Társult tumorok előfordulása krónikus lymphoid leukémiában.] Orv Hetil. 2016; 157: 1752–1756. [Hungarian]

  • 5

    Jakó J, Szerafin L. Occurrence of associated tumours in acute myeloid leukemia, chronic myeloid leukemia and Philadelphia-negative chronic myeloproliferative disorders. [Társult tumorok előfordulása akut myeloid leukémiában, krónikus myeloid leukémiában és Philadelphia-negatív krónikus myeloproliferativ betegségekben.] Hemat Transzf. 2018; 51: 204–213. [Hungarian]

  • 6

    Vannucchi AM, Masala G, Antonioli E, et al. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Epidemiol Biomark Prev. 2009; 18: 2068–2073.

  • 7

    Frederiksen H, Körmendiné Farkas D, Christiansen CF, et al. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood 2011; 118: 6515–6520.

  • 8

    Laurenti L, Tarnani M, Nichele I, et al. The coexistence of chronic lymphocytic leukemia and myeloproliferative neoplasms: a retrospective multicentric GIMEMA experience. Am J Hematol. 2011; 86: 1007–1012.

  • 9

    Rumi E, Passamonti F, Elena C, et al. Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. Haematologica 2011; 96: 454–458.

  • 10

    Masarova L, Newberry KJ, Pierce SA, et al. Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome. Leuk Res. 2015; 39: 822–827.

  • 11

    Marcheselli L, Polliack A., Tadmor T. Impact of therapy on the development of second malignancies in essential thrombocythemia and polycythemia vera: Are we comfortable about this? Leuk Lymphoma 2016; 57: 6–7.

  • 12

    Masarova L, Cherry M, Newberry KJ, et al. Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera – single center experience. Leuk Lymphoma 2016; 57: 237–239.

  • 13

    Todisco D, Manshouri T, Verstovsek S, et al. Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics. Leuk Lymphoma 2016; 57: 1054–1059.

  • 14

    Brunner AM, Hobbs G, Jalbut MM, et al. A population-based analysis of second malignancies among patients with myeloproliferative neoplams in the SEER database. Leuk Lymphoma 2016; 57: 1197–1200.

  • 15

    Várady E, Deák B, Molnár Zs., et al. Second malignancies after treatment for Hodgkin’s disease. Leuk Lymphoma 2001; 42: 1275–1281.

  • 16

    Keresztes K, Miltényi Zs, András Cs, et al. A second malignancies in managing Hodgkin’s disease. [Második malignus tumor gondozott Hodgkin-kóros betegeinknél.] Magyar Onkol. 2002; 46: 247–251. [Hungarian]

  • 17

    Pál I, Illés Á, Pál T, et al. Multiple myeloma and seconder tumours. [Myeloma multiplex és szekunder tumorok.] Hemat Transzf. 2017; 50: 39-42. [Hungarian]

  • 18

    Pagano L, Pulsoni A, Vignetti M, et al. Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials. Ann Oncol. 2005; 16: 228–233.

  • 19

    Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol. 2008; 35: 418– 429.

  • 20

    Fianchi L, Pagano L, Piciocchi A, et al. Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. Am J Hematol. 2015; 90(5): E80–85.

  • 21

    McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: When genetics and environment collide. Nat Rev Cancer 2017; 17: 513–527.

  • 22

    Morton LM, Dores GM, Tucker MA, et al. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975–2008. Blood; 2013; 121: 2996–3004.

  • 23

    Sakata-Yanagimoto M, Yokoyama Y, Muto H, et al. A nationwide survey of co-occurrence of malignant lymphomas and myelodysplastic syndromes/myeloproliferative neoplasms. Ann Hematol. 2016; 95: 829–830.

  • 24

    Masarova L, Todisco G, Manshouri T, et al. Therapy-related myelofibrosis does not appear to exist. Blood Adv. 2017; 1: 863–866.

  • 25

    Landtblom AR, Bower H, Andersson TM, et al. Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients. Leukemia 2018; .

    • Crossref
    • Export Citation
  • 26

    Jakó J, Szerafin L. Simultaneous occurrence of polycythemia vera and chronic lymphocytic leukemia. [Polycythaemia vera és krónikus lymphoid leukaemia egyidejű előfordulása.] Hemat Transzf. 2007; 40: 21–24. [Hungarian]

  • 27

    Popov VM, Dobrea C-M, Popescu M, et al. Diffuse large B-cell lymphoma and polycythemia vera discovered at the onset – a rare association and its possible importance in lymphoma prognosis. Rom J Morphol Embryol. 2016; 57: 313–318.

  • 28

    Palandri F, Derenzini E, Ottaviani E, et al. Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience. Leuk Lymphoma 2009; 50: 481–484.

  • 29

    Shervani S, Durban C, Williams C, et al. Treating a simultaneous presentation of multiple myeloma and Hodgkin’s lymphoma. Ann Hematol Oncol. 2018; 5: 1202.

  • 30

    Weisenberg E, Anastasi J, Adeyanju M, et al. Hodgkin’s disease associated with chronic lymphocytic leukemia: eight additional cases, including two of the nodular lymphocyte predominant type. Am J Clin Pathol. 1995; 103: 479–484.

  • 31

    Collinge E, Loron S, Larcher M-V, et al. Elderly patients (age 70 years or older) with secondary acute myeloid leukemia or acute myeloid leukemia development concurrently to another malignant disease. Clin Lymph Myeloma and Leuk. 2018; 18: e211–e218.

  • 32

    Fenk R, Neubauer F, Bruns J, et al. Secondary primary malignancies in patients with multiple myeloma treated with high-dose chemotherapy and autologous blood stem cell transplantation. Brit J Haematol. 2012; 156: 672–686.

  • 33

    Mahindra A, Raval G, Mehta P, et al. New cancers after autotransplantations for multiple myeloma. Biol Blood Marrow Transplant. 2015; 21: 738–745.

  • 34

    Ito S, Fujiwara S, Mashima K, et al. Development of acute myeloid leukemia in patients with untreated chronic lymphocytic leukemia. Ann Hematol. 2017; 96: 719–724.

  • 35

    Yilmaz M, Durusoy SS, Kizikli A, et al. Association of chronic lymphocytic leukemia and acute myeloid leukemia in three patients: cases with the concomitant presence of two different malignant clones. J Leuk. 2018; 6: 250–255.

  • 36

    Szerafin L, Jakó J. Chronic myeloid leukaemia following polycythaemia vera (A molecularly documented case report). [Polycythaemia verát követően kialakult krónikus myeloid leukaemia (esetismertetés).] Hemat Transzf. 2011; 44: 102–106. [Hungarian]

  • 37

    Fallah M, Kharazmi E, Sundquist J, et al. Higher risk of primary cancers after polycythaemia vera and vice versa. Brit J Haematol. 2011; 153: 273–285.

  • 38

    Ipek Y-H, Fehmi H, Meliha N. Hairy cell leukemia followed by polycythemia vera: report of the first case. Oxford Med Case Reports 2016; 3: 28–30.

  • 39

    Darawshy F, Ben-Yehuda A, Atlan K, et al. Chronic lymphocytic leukemia and myelofibrosis. Case Rep Hematol. 2018; .

    • Crossref
    • Export Citation
  • 40

    Wolleschak D, Heidel FH. Chronic myelogenous leukemia evolving after treatment of multiple myeloma. Blood 2016; 128: 146.

  • 41

    Ghirardi A, Carobbio A, Masciulli A, et al. Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydoxyurea. Blood Cancer J. 2018; .

    • Crossref
    • Export Citation
  • 42

    Miranda MB, Lauseker M, Kraus M-P, et al. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV. Leukemia 2016; 30: 1255–1262.

  • 43

    Hernández-Boluda J-C, Cervantes F, Alvarez A, et al. Non-Hodgkin’s lymphoma following untreated essential thrombocythemia. Leuk Lymphoma 2000; 36: 421–423.

  • 44

    Bhatt VR, Bociek RG, Yuan J, et al. Leukemic diffuse large B-cell lymphoma in a patient with myeloproliferative disorder. J Natl Compr Canc Netw. 2015; 13: 281–287.

  • 45

    Porpaczy E, Tripolt S, Hoelbl-Kovacic A, et al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood 2018; 132: 694–706.

  • 46

    Islam MS. Concurrent chronic lymphocytic leukaemia and hairy cell leukaemia after initial treatment for hairy cell leukaemia. Ann Hematol Oncol 2018; 5: 1206.

  • 47

    Majhail NS, Lichtin AE. Rare coexistence of multiple myeloma with essential thrombocythemia: Report of two cases. Haematologica 2007; 88(3) e34–e35.

  • 48

    Labotka RJ, Sotelo-Avila C, Hruby MA. Hodgkin’s disease in a child with acute lymphoblastic leukemia. Cancer 1983; 52: 846–850.

  • 49

    Neglia JP, Meadows AT, Robison LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med. 1991; 325: 1330–1336.

  • 50

    Godfrey J, Leukam MJ, Smith SM. An update in treating transformed lymphoma. Best Pract Res Clin Haematol. 2018; 31: 251–261.